Oxford Immunotec Global PLC Overview
Valuation check: OXFD's ROE is -9.14%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-9.14%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Oxford Immunotec Global PLC (OXFD) currently reports a ROE of -9.14%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Oxford Immunotec Global PLC's ROE history and peer comparisons.
Oxford Immunotec Global PLC's ROE of -9.14% is lower than the Healthcare sector average of 11.15%. That is roughly 181.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Oxford Immunotec Global PLC's current -9.14% should be judged against Healthcare norms (sector average: 11.15%) and against OXFD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -9.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Oxford Immunotec Global PLC, and consider following OXFD for alerts when major investors trade the stock.
Oxford Immunotec Global PLC is classified in the Healthcare sector. On ROE, it currently shows -9.14% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OXFD with unrelated industries.
